Larimar Therapeutics Inc
NASDAQ:LRMR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.71
5.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Larimar Therapeutics Inc
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The firm's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The firm's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.
Phase II Data: Larimar reported top-line results from the 25-milligram cohort of its Phase II trial for CTI-1601 in Friedreich’s Ataxia, showing the drug was generally well tolerated and achieved steady state by day 14.
Biomarker Increases: The trial showed a median placebo-adjusted increase of 3.5 picograms per microgram protein in skin frataxin after 14 days of daily dosing, with all evaluated patients on CTI-1601 having increases in skin frataxin.
Safety: No serious adverse events were reported; the most common issues were mild/moderate injection site reactions. One patient discontinued due to an allergic reaction that resolved with standard treatment.
Next Steps: Larimar submitted the data to the FDA as required and plans an FDA meeting later this quarter to seek clearance for a 50-milligram cohort; an update is expected in the third quarter.
Financials: Larimar ended the last quarter with a cash balance of about $111.5 million, providing runway into the second half of 2024.
